The technology is being developed by a company called C2N Diagnostics, which also made earlier blood tests for Alzheimer’s.

The scientists concluded that while the two markers perform similarly, they yield complementary information, and sequential ...

Dementia affects millions of people worldwide, causing a serious impact on the economy and the healthcare system. Alzheimer’s ...

BIIB080 marks the first antisense oligonucleotide targeting tau to enter clinical development for the treatment of Alzheimer ...

The blood test for eMTBR-tau243 shows strong correlation with tau pathology, enhancing Alzheimer's diagnosis and monitoring ...

Discover the breakthrough Alzheimer's test that measures tau tangles in blood, simplifying Alzheimer's diagnosis and ...

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical ...

Enigma Biomedical USA, Inc. (EB USA) today announced that it is starting a collaboration with the Boston University Chronic Traumatic Encephalopathy (CTE) Center and the Concussion Legacy Foundation.

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q4 2024 Earnings Call Transcript March 27, 2025 Acumen Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were ...